PKBO — Peak Bio Income Statement
0.000.00%
- $0.22m
- $4.24m
- $0.61m
Annual income statement for Peak Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Revenue | |||
Total Revenue | 0 | 0.528 | 0.608 |
Selling / General / Administrative Expenses | |||
Research And Development | |||
Unusual Expense / Income | |||
Total Operating Expenses | 13.3 | 8.73 | 12.9 |
Operating Profit | -13.3 | -8.2 | -12.3 |
Total Net Non Operating Interest Income / Expense | |||
Other Net Non Operating Costs | |||
Net Income Before Taxes | -13.3 | -8.21 | -13.2 |
Provision for Income Taxes | |||
Net Income After Taxes | -13.3 | -8.29 | -13.1 |
Net Income Before Extraordinary Items | |||
Net Income | -13.3 | -8.29 | -13.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||
Income Available to Common Shareholders Including Extraordinary Items | |||
Diluted Net Income | -13.3 | -8.29 | -13.1 |
Diluted Weighted Average Shares | |||
Basic EPS Including Extraordinary Items | |||
Diluted EPS Including Extraordinary Items | |||
Diluted EPS Excluding Extraordinary Items | |||
Normalised Income Before Taxes | |||
Normalised Income After Taxes | |||
Normalised Income Available to Common Shareholders | |||
Diluted Normalised EPS | -0.615 | -0.408 | -0.589 |